Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Eisai adds online patient stories to Belviq marketing

Belviq Voices 'online community' will featureweight loss patient experiences

Eisai Belviq Voices lorcaserin obesityEisai has set up an “online community of personal weight loss stories” as part of the marketing efforts behind its obesity brand Belviq (lorcaserin HCl).

Named Belviq Voices, it features patient stories alongside information on obesity, its associated health risks and the need for action.

The company said the community is meant to "inspire and encourage honest, open conversation with physicians".

Frank Ciriello, president of Eisai's global neurology business unit, said: "At Eisai, our patients are our first priority. With obesity rates continuing to escalate across the nation, it is important that patients have the right tools, resources and support to help them lead a healthier lifestyle in a way that works for them.

“Belviq Voices aims to inspire action and encourage conversations among patients and physicians to address obesity, a chronic and progressive disease that needs to be treated." 

Somewhat curiously, although branded by the company as an 'online patient community', Belviq Voices only exists as a microsite within MultiVu.com, a multimedia production group within press release distribution firm PR Newswire. This is despite Eisai's development partner Arena Pharmaceuticals having registered the URL BelviqVoices.com earlier this year.

So, rather than having a standalone community, Eisai has chosen to work with MultiVu to host a series of patient stories in pdf form, downloadable video and information about obesity.

A company spokesman told PMLiVE that Eisai planned to update its Belviq Voices microsite with additional content  throughout 2015.

The company is also hoping that patients on its drug will want to share their own weight loss story and has set up a telephone mailbox for them to do so.

Approved in 2012 Belviq, which activates the 5-HT2C receptor in the brain and is thought to work by increasing feelings of satiety when consuming food, was the first new obesity drug to be licensed in 13 years.

However, it has quickly faced new competition as two other obesity drugs - Takeda's Contrave and Vivus' Qsymia - came to the market not long award Belviq.

To support its brand Eisai doubled the size of Belviq's sales force, launched a new patient savings card last month and now has added this additional element into its online marketing.

26th February 2015

From: Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcircle

We're Healthcircle – an award-winning healthcare advertising and creative communications agency, offering a holistic approach to brand health. With a...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics